— Know what they know.
Not Investment Advice

PVLA NASDAQ

Palvella Therapeutics, Inc.
1W: -2.6% 1M: -11.3% 3M: +35.3% YTD: +15.6% 1Y: +399.0%
$113.99
-1.93 (-1.66%)
 
Weekly Expected Move ±9.3%
$93 $104 $114 $125 $135
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 38 · $1.3B mcap · 7M float · 4.00% daily turnover · Short 61% of daily vol

Balance Sheet Trends

Total Assets
$60M -32.5% ▼
5Y CAGR: -10.7%
Total Liabilities
$32M +23.2% ▲
5Y CAGR: -15.7%
Shareholders Equity
$28M -55.3% ▼
5Y CAGR: -2.0%
Cash & Investments
$58M -30.6% ▼
5Y CAGR: -3.8%
Total Debt
$633K +0.0% ▲
5Y CAGR: -48.2%
Net Debt
-$57M +31.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$118M$16M$7M$84M$58M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$118M$16M$7M$84M$58M
Net Receivables$3M$0$0$2M$0
Inventory$0$0$0$0$0
Other Current Assets$7M$471K$198K$2M$1M
Total Current Assets$128M$17M$8M$88M$59M
Property, Plant & Equip.$23M$0$0$0$572K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$3M$0$0$0$0
Total Non-Current Assets$26M$0$0$0$572K
Total Assets$154M$17M$8M$88M$60M
— Liabilities —
Accounts Payable$9M$3M$936K$5M$5M
Short-Term Debt$1M$0$0$0$202K
Deferred Revenue$25M$0$0$0$0
Other Current Liabilities$12M$921K$344K$6M$11M
Total Current Liabilities$51M$6M$2M$12M$11M
Long-Term Debt$0$0$0$0$431K
Other Non-Current Liab.$0$34M$9M$14M$20M
Total Non-Current Liabilities$52M$34M$9M$14M$20M
Total Liabilities$103M$40M$11M$26M$32M
— Equity —
Common Stock$72K$0$0$11K$12K
Retained Earnings-$257M-$95M-$76M-$94M-$135M
Accumulated OCI$829K$0$0$3K$83K
Total Stockholders Equity$51M-$23M-$4M$63M$28M
Total Liabilities & Equity$154M$17M$8M$88M$60M
— Key Metrics —
Total Debt$15M$0$0$0$633K
Net Debt-$103M-$16M-$7M-$84M-$57M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms